Leukemia Research
Volume 26, Issue 3 , Pages 271-280 , March 2002

Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol

  • Igor Semenov

      Affiliations

    • Department of Pediatrics (Hematology-Oncology), Children's Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    • ,
  • Canan Akyuz

      Affiliations

    • Department of Pediatrics (Hematology-Oncology), Children's Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    • Department of Pediatrics (Oncology), Faculty of Medicine, Hacettepe University, Ankara, Turkey
    • ,
  • Vera Roginskaya

      Affiliations

    • Department of Pediatrics (Hematology-Oncology), Children's Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    • ,
  • Dharminder Chauhan

      Affiliations

    • Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    • ,
  • Seth J Corey

      Affiliations

    • Department of Pediatrics (Hematology-Oncology), Children's Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    • Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-412-692-5055; fax: +1-412-692-6473

Received 27 December 2000 ,Accepted 16 May 2001.

References 

  1. Barlogie B. Advances in therapy of multiple myeloma: lessons from acute leukemia. Clin. Cancer Res. 1997;3:2605–2613
  2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. New Engl. J. Med. 1994;330:484–489
  3. Tsuchiya J, Murakami H, Kanoh T, Kosaka M, Sezaki T, Mikuni C, et al  Ten-year survival and prognostic factors in multiple myeloma. Br. J. Haematol. 1994;87:832–834
  4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854
  5. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl. J. Med. 1996;335:91–97
  6. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793
  7. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995;16:7–11
  8. Raje N, Anderson K. Thalidomide–a revival story. New Engl. J. Med. 1999;341:1606–1609
  9. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl. J. Med. 1999;341:1565–1571
  10. Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, et al. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp. Hematol. 1997;25:1367–1377
  11. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3–21
  12. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 2000;105:3–7
  13. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 2000;92:376–387 In process citation
  14. De Azevedo WF, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA. 1996;93:2735–2740
  15. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 1996;56:4856–4861
  16. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996;56:2973–2978
  17. Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C, Stadler WM. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother. Pharmacol. 1999;44:81–87
  18. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood. 1997;90:4307–4312
  19. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 1998;91:458–465
  20. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood. 1998;91:2482–2490
  21. Corey SJ, Burkhardt AL, Bolen JB, Geahlen RL, Tkatch LS, Tweardy DJ. Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. Proc. Natl. Acad. Sci. USA. 1994;91:4683–4687
  22. Tai YT, Teoh G, Shima Y, Chauhan D, Treon SP, Raje N, et al. Isolation and characterization of human multiple myeloma cell enriched populations. J. Immunol. Methods. 2000;235:11–19
  23. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92:3804–3816
  24. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999;59:4634–4641
  25. Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, Bataille R, et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br. J. Haematol. 1999;107:392–395
  26. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. 1999;5:1876–1883
  27. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. 2000;18:371–375
  28. Innocenti F, Stadler WM, Iyer L, Ramirez J, Vokes EE, Ratain MJ. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin. Cancer Res. 2000;6:3400–3405
  29. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down- regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000;96:393–397

PII: S0145-2126(01)00103-5

Leukemia Research
Volume 26, Issue 3 , Pages 271-280 , March 2002

Article Tools

* Image Usage & Resolution